A radioimmunoassay for prostatic acid phosphatase.
A solid phase radioimmunoassay for human prostatic acid phosphatase has demonstrated substantially greater biochemical sensitivity than a standard enzymatic method for which p-nitrophenylphosphate was used as substrate. Preliminary data indicate that the radioimmunochemical approach can precisely classify 43% stage I-II and 94% stage III-IV prostate cancers. In contrast, the standard enzymatic methods correctly classified only 9% stage I-II and 46% stage III-IV cancers. It is clinically apparent that a radioimmunochemical approach for the measurement of human prostatic phosphatase may have distinct potential in the clinical diagnosis of prostate cancer.
D000135:Acid Phosphatase / Q000032:analysis*; D000328:Adult; D000368:Aged; D003951:Diagnostic Errors; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000201:enzymology; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000201:enzymology*; D011863:Radioimmunoassay / Q000379:methods*
D000135:Acid Phosphatase